Economic impact of disease progression in follicular non-Hodgkin lymphoma
Economic impact of disease progression in follicular non-Hodgkin lymphoma
复制标题
DOI：
10.3109/10428194.2011.592623
复制
发表时间：
2011-11-01
影响因子：
2.6
通讯作者：
Reyes, Carolina
中科院分区：
文献类型：
--
作者：
Beveridge, Roy;Satram-Hoang, Sacha;Reyes, Carolina
使用回溯性索赔数据库，我们估计了在以社区为基础的门诊环境中接受治疗的滤泡性非霍奇金淋巴瘤(f-NHL)患者进展的经济成本。2006年7月1日至2009年12月31日期间接受治疗的f-NHL患者根据是否经历进展性疾病(PD)被分为两组。比较帕金森病患者与非帕金森病患者的每位患者每月费用(PPPM)。随访时间在疾病状态的最后一次输入时或缓解/稳定疾病或进展日期后6个月被审查。在确诊的1002名f-NHL患者中，268人进展，734人没有进展。在6个月的随访期内，帕金森病患者的平均总购买力平价显著高于非帕金森病患者(3,527美元对860美元；差异=2,667美元；p<；0.001)。这种成本差异在评估的所有资源类别中持续存在。这项研究的结果表明，延缓f-NHL患者进展的治疗可能会导致潜在的成本节约。
Using a retrospective claims database, we estimated the economic costs of progression among patients with follicular non-Hodgkin lymphoma (f-NHL) treated in an outpatient community-based setting. Patients with f-NHL who received care between 1 July 2006 and 31 December 2009 were categorized into two cohorts based on whether they experienced progressive disease (PD) or not. Costs per patient per month (PPPM) were compared between patients with PD versus non-PD. Follow-up time was censored at the last entry for disease status or 6 months after the date of remission/stable disease or progression. Of the 1002 patients with f-NHL identified, 268 progressed and 734 did not. The mean overall costs PPPM over the 6-month follow-up period were significantly higher for patients with PD versus non-PD ($3527 vs. $860; difference = $2667; p < 0.001). This cost difference persisted within all resource categories evaluated. Results of this study indicate that therapies which delay progression for patients with f-NHL may result in potential cost savings.